These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 34788507)

  • 1. Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.
    George LA; Monahan PE; Eyster ME; Sullivan SK; Ragni MV; Croteau SE; Rasko JEJ; Recht M; Samelson-Jones BJ; MacDougall A; Jaworski K; Noble R; Curran M; Kuranda K; Mingozzi F; Chang T; Reape KZ; Anguela XM; High KA
    N Engl J Med; 2021 Nov; 385(21):1961-1973. PubMed ID: 34788507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
    Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
    N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
    Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
    N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
    George LA; Sullivan SK; Giermasz A; Rasko JEJ; Samelson-Jones BJ; Ducore J; Cuker A; Sullivan LM; Majumdar S; Teitel J; McGuinn CE; Ragni MV; Luk AY; Hui D; Wright JF; Chen Y; Liu Y; Wachtel K; Winters A; Tiefenbacher S; Arruda VR; van der Loo JCM; Zelenaia O; Takefman D; Carr ME; Couto LB; Anguela XM; High KA
    N Engl J Med; 2017 Dec; 377(23):2215-2227. PubMed ID: 29211678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1-2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B.
    Chowdary P; Shapiro S; Makris M; Evans G; Boyce S; Talks K; Dolan G; Reiss U; Phillips M; Riddell A; Peralta MR; Quaye M; Patch DW; Tuddenham E; Dane A; Watissée M; Long A; Nathwani A
    N Engl J Med; 2022 Jul; 387(3):237-247. PubMed ID: 35857660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
    Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
    N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B.
    Cuker A; Kavakli K; Frenzel L; Wang JD; Astermark J; Cerqueira MH; Iorio A; Katsarou-Fasouli O; Klamroth R; Shapiro AD; Hermans C; Ishiguro A; Leavitt AD; Oldenburg JB; Ozelo MC; Teitel J; Biondo F; Fang A; Fuiman J; McKay J; Sun P; Rasko JEJ; Rupon J;
    N Engl J Med; 2024 Sep; 391(12):1108-1118. PubMed ID: 39321362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of liver-directed, adeno-associated vector-mediated gene therapy in the canine model of hemophilia A.
    Batty P; Mo AM; Hurlbut D; Ishida J; Yates B; Brown C; Harpell L; Hough C; Pender A; Rimmer EK; Sardo Infirri S; Winterborn A; Fong S; Lillicrap D
    Blood; 2022 Dec; 140(25):2672-2683. PubMed ID: 35405003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.
    Mahlangu J; Oldenburg J; Paz-Priel I; Negrier C; Niggli M; Mancuso ME; Schmitt C; Jiménez-Yuste V; Kempton C; Dhalluin C; Callaghan MU; Bujan W; Shima M; Adamkewicz JI; Asikanius E; Levy GG; Kruse-Jarres R
    N Engl J Med; 2018 Aug; 379(9):811-822. PubMed ID: 30157389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B.
    George LA; Ragni MV; Rasko JEJ; Raffini LJ; Samelson-Jones BJ; Ozelo M; Hazbon M; Runowski AR; Wellman JA; Wachtel K; Chen Y; Anguela XM; Kuranda K; Mingozzi F; High KA
    Mol Ther; 2020 Sep; 28(9):2073-2082. PubMed ID: 32559433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV-mediated gene transfer for hemophilia.
    High KA
    Ann N Y Acad Sci; 2001 Dec; 953():64-74. PubMed ID: 11795424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice.
    Sarkar R; Mucci M; Addya S; Tetreault R; Bellinger DA; Nichols TC; Kazazian HH
    Hum Gene Ther; 2006 Apr; 17(4):427-39. PubMed ID: 16610930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and efficacy of factor IX gene therapy in hemophilia B.
    Nathwani AC; Reiss UM; Tuddenham EG; Rosales C; Chowdary P; McIntosh J; Della Peruta M; Lheriteau E; Patel N; Raj D; Riddell A; Pie J; Rangarajan S; Bevan D; Recht M; Shen YM; Halka KG; Basner-Tschakarjan E; Mingozzi F; High KA; Allay J; Kay MA; Ng CY; Zhou J; Cancio M; Morton CL; Gray JT; Srivastava D; Nienhuis AW; Davidoff AM
    N Engl J Med; 2014 Nov; 371(21):1994-2004. PubMed ID: 25409372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
    Madan B; Ozelo MC; Raheja P; Symington E; Quon DV; Leavitt AD; Pipe SW; Lowe G; Kenet G; Reding MT; Mason J; Wang M; von Drygalski A; Klamroth R; Shapiro S; Chambost H; Dunn AL; Oldenburg J; Chou SC; Peyvandi F; Millar CM; Osmond D; Yu H; Dashiell-Aje E; Robinson TM; Mahlangu J
    J Thromb Haemost; 2024 Jul; 22(7):1880-1893. PubMed ID: 38614387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors.
    Sabatino DE; Lange AM; Altynova ES; Sarkar R; Zhou S; Merricks EP; Franck HG; Nichols TC; Arruda VR; Kazazian HH
    Mol Ther; 2011 Mar; 19(3):442-9. PubMed ID: 21081906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in gene therapy for hemophilia: basis, current status, and future perspectives.
    Ohmori T
    Int J Hematol; 2020 Jan; 111(1):31-41. PubMed ID: 30083852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A.
    Konkle BA; Shapiro AD; Quon DV; Staber JM; Kulkarni R; Ragni MV; Chhabra ES; Poloskey S; Rice K; Katragadda S; Fruebis J; Benson CC
    N Engl J Med; 2020 Sep; 383(11):1018-1027. PubMed ID: 32905674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A.
    Long BR; Robinson TM; Day JRS; Yu H; Lau K; Imtiaz U; Patton KS; de Hart G; Henshaw J; Agarwal S; Vettermann C; Zoog SJ; Gupta S
    Mol Ther; 2024 Jul; 32(7):2052-2063. PubMed ID: 38796703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.